AVEO Pharmaceuticals, Inc. (AVEO) Is At $2.25 Formed Wedge; 2 Bullish Analysts Covering Westpac Banking (WBK)

Westpac Banking Corporation (NYSE:WBK) Logo

Among 3 analysts covering Westpac Banking (NYSE:WBK), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Westpac Banking had 3 analyst reports since September 2, 2015 according to SRatingsIntel. Credit Suisse upgraded the stock to “Outperform” rating in Wednesday, September 2 report. On Tuesday, May 24 the stock rating was upgraded by Macquarie Research to “Outperform”. The stock of Westpac Banking Corporation (NYSE:WBK) has “Neutral” rating given on Thursday, August 11 by JP Morgan. See Westpac Banking Corporation (NYSE:WBK) latest ratings:

AVEO Pharmaceuticals, Inc. (AVEO) formed wedge down with $2.14 target or 5.00% below today’s $2.25 share price. AVEO Pharmaceuticals, Inc. (AVEO) has $346.84 million valuation. The stock decreased 6.25% or $0.15 during the last trading session, reaching $2.25. About 2.15M shares traded or 16.34% up from the average. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has risen 182.80% since June 26, 2017 and is uptrending. It has outperformed by 170.23% the S&P500. Some Historical AVEO News: 10/05/2018 – Sphera Funds Management Exits Position in Aveo; 21/03/2018 – AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC; 09/05/2018 – A Healthy Lifestyle Calls For Healthy Contacts; 21/03/2018 – AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory; 09/04/2018 – Aveo at HC Wainwright Global Biotechnology Conference Tomorrow; 19/04/2018 – GERMAN GBA SEES NO ADDITIONAL BENEFIT TO AVEO’S FOTIVDA; 08/05/2018 – STAT Plus: Biotech updates: Amicus, Aveo Oncology, Akcea Therapeutics, and Ionis Pharma; 13/03/2018 – AVEO PHARMACEUTICALS INC QUARTERLY SHR LOSS $0.08; 08/05/2018 – AVEO Pharmaceuticals 1Q Loss/Shr 8c; 21/03/2018 – AVEO: Activity Shown in TKI Refractory Patients Compares Favorably With Data Published for Other TKI Agents

Analysts await AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report earnings on August, 8. They expect $-0.06 earnings per share, up 25.00% or $0.02 from last year’s $-0.08 per share. After $-0.08 actual earnings per share reported by AVEO Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

Since April 6, 2018, it had 40 insider purchases, and 0 insider sales for $27.70 million activity. $503,423 worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was bought by Florence Anthony A. Jr.. Another trade for 70,873 shares valued at $151,250 was made by Viswanathan Ravi on Tuesday, May 8. MOTT DAVID M bought $151,250 worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Tuesday, May 8. $591 worth of stock was bought by Growth Equity Opportunities IV – LLC on Wednesday, May 30. 236,479 shares valued at $503,423 were bought by BASKETT FOREST on Thursday, May 17. SANDELL SCOTT D also bought $2.12 million worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Friday, April 6. $2.12M worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was bought by MAKOWER JOSHUA on Friday, April 6.

Among 3 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharmaceuticals has $7 highest and $200 lowest target. $5.67’s average target is 152.00% above currents $2.25 stock price. AVEO Pharmaceuticals had 15 analyst reports since March 30, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 9 by Piper Jaffray. The firm earned “Buy” rating on Monday, February 12 by FBR Capital. The stock has “Buy” rating by FBR Capital on Tuesday, March 13. The stock has “Buy” rating by FBR Capital on Monday, June 26. The rating was maintained by Piper Jaffray on Thursday, March 29 with “Buy”. The firm has “Buy” rating by Piper Jaffray given on Monday, August 28. The rating was initiated by FBR Capital on Wednesday, March 30 with “Outperform”. FBR Capital maintained the stock with “Buy” rating in Thursday, December 7 report. Piper Jaffray initiated the stock with “Overweight” rating in Thursday, May 19 report. The stock has “Buy” rating by FBR Capital on Thursday, March 22.

Investors sentiment decreased to 1.24 in 2018 Q1. Its down 1.57, from 2.81 in 2017Q4. It dropped, as 12 investors sold AVEO Pharmaceuticals, Inc. shares while 17 reduced holdings. 16 funds opened positions while 20 raised stakes. 57.68 million shares or 3.14% less from 59.55 million shares in 2017Q4 were reported. Spark Inv Mngmt Ltd Liability Corporation reported 164,300 shares. 79,134 were accumulated by One Trading Lp. Sg Americas Secs holds 12,085 shares or 0% of its portfolio. Pnc Gp holds 0% or 22,000 shares. Moreover, Blackrock Inc has 0% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 1.88 million shares. Scotia Inc accumulated 10,000 shares or 0% of the stock. Granahan Invest Management Inc Ma reported 154,378 shares or 0.03% of all its holdings. Vanguard Group Inc Inc Inc holds 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 4.52 million shares. Asset Mgmt Inc stated it has 0.1% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). State Street Corp invested in 141,340 shares or 0% of the stock. 3,634 were reported by Manufacturers Life Insur The. Venbio Select Advisor has invested 0.45% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Clear Harbor Asset Mgmt Limited Liability holds 0.02% or 28,000 shares in its portfolio. Goldman Sachs owns 782,330 shares or 0% of their US portfolio. Cubist Systematic Strategies Llc reported 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO).

The stock decreased 1.83% or $0.4 during the last trading session, reaching $21.4. About 202,292 shares traded. Westpac Banking Corporation (NYSE:WBK) has declined 6.98% since June 26, 2017 and is downtrending. It has underperformed by 19.55% the S&P500. Some Historical WBK News: 26/04/2018 – Westpac Mortgages 90+ Day Delinquencies in Australia 0.67% at End-December; 06/05/2018 – WESTPAC 1H CASH PROFIT A$4.25B; EST. A$4.21B; 24/05/2018 – ♫ Reuters Insider – Asia Insight: China will “defend its interests” as U.S. probes car and truck imports; 17/05/2018 – WESTPAC BANKING CORP – APPOINTS CAROLYN MCCANN TO NEW POSITION OF GROUP EXECUTIVE, CUSTOMER & CORPORATE RELATIONS; 16/04/2018 – FLETCHER SAYS NZ$500M BANKING FACILITY W/ ANZ, MUFG, WESTPAC; 24/05/2018 – WESTPAC BANKING CORP – NOTES TODAY’S FEDERAL COURT RULING IN RELATION TO ASIC’S CLAIM AGAINST WESTPAC CONCERNING BANK BILL SWAP RATE; 23/04/2018 – Fitch Affirms Westpac NZ’s Mortgage Covered Bonds at ‘AAA’; Outlook Stable; 26/04/2018 – WESTPAC REAFFIRMS PERFORMANCE OF MORTGAGE PORTFOLIO-WBC.AX; 26/04/2018 – WESTPAC BANKING CORP WBC.AX – AT 31 DECEMBER 2017 WESTPAC’S MORTGAGE 90+ DAY DELINQUENCIES IN AUSTRALIA WERE 0.67%; 23/05/2018 – Sky News Australia: #BREAKING: The Federal Court has found @Westpac engaged in unconscionable conduct on four occasions by

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Positions Chart